Considering the crucial role of autophagy in AD, we speculated that targeting AKT/mTOR‐mediated autophagy signaling may offer novel therapeutic avenues for sevoflurane‐induced cognitive impairment associated with tau pathology. Here, MAPT is linked to Alzheimer disease.